Valbiotis (XPAR:ALVAL) Revenue: €0.91 Mil (TTM As of Dec. 2025)


XPAR:ALVAL Valbiotis SA XPAR:ALVAL
60 GF Score
Price €0.79
GF Value €1.48
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Revenue?

Valbiotis XPAR:ALVAL +1.67% 60 Revenue is €0.91 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVAL with a GF Score™ of 60/100 and a GF Value™ of €1.48 (Possible Value Trap). The stock has 6 warning signs investors should review.

Valbiotis's revenue for the six months ended in Dec. 2025 was €0.57 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €0.91 Mil. Valbiotis's Revenue per Share for the six months ended in Dec. 2025 was €0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.

Warning Sign:

Valbiotis SA revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Valbiotis was 309.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -16.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 11 years, Valbiotis's highest 3-Year average Revenue per Share Growth Rate was 639.90% per year. The lowest was -29.90% per year. And the median was 7.05% per year.


Valbiotis  (XPAR:ALVAL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Valbiotis Revenue Related Terms


Valbiotis Revenue Historical Data

* Premium members only.

The historical data trend for Valbiotis's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valbiotis Revenue Chart

Valbiotis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.79 4.73 0.18 0.91

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.04 0.14 0.33 0.57

XPAR:ALVAL vs KHC, GIS, HRL: Revenue Comparison

For the Packaged Foods subindustry, Valbiotis's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valbiotis Revenue vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's Revenue distribution charts can be found below:

* The bar in red indicates where Valbiotis's Revenue falls into.


XPAR:ALVAL
60GF Score
Valbiotis SA XPAR:ALVAL
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valbiotis Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of €0.91 Mil mean?
Valbiotis (XPAR:ALVAL) has a Revenue of €0.91 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Valbiotis and its competitors.
Is Valbiotis' Revenue too high?
Valbiotis' current Revenue is €0.91 Mil. Overall, Valbiotis has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Revenue compare to KHC and GIS?
Valbiotis' Revenue of €0.91 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Consumer Packaged Goods company?
A good Revenue depends on the Consumer Packaged Goods industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Valbiotis and its competitors. Valbiotis's current Revenue is €0.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.48, compared to a current price of €0.79 — trading 46.6% below its estimated fair value. The current Revenue is €0.91 Mil. Valbiotis' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Revenue is €0.91 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.79 is trading 46.6% below its estimated GF Value™ of €1.48. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Revenue: €0.91 Mil
  • GF Value™: €1.48 vs. price of €0.79 (46.6% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
60GF Score

Get the complete analysis for XPAR:ALVAL

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.48
GF Value